Market Research Logo

Norway Pharmaceuticals and Healthcare Report Q3 2015

BMI View: Against a backdrop of high per capita spending on medicines, an ageing population andsustained growth in healthcare expenditure, Norway is expected to remain among the seven most attractivemarkets in Western Europe to drug manufacturers in the foreseeable future. Despite a comparativelysmaller market size, Norway's pharmaceutical sector, as distinct from several contracting drug markets inthe region, is expected to continue on its long-standing positive growth trajectory, creating opportunitiesfor drugmakers.

Headline Expenditure Projections

Pharmaceuticals: NOK20.26bn (USD3.05bn) in 2014 to NOK20.71bn (USD2.68bn) in 2015; +2.23% inlocal currency terms and -12.1% in US dollar terms. Forecast in line with last quarter.

Healthcare: NOK298.24bn (USD44.90bn) in 2014 to DKK308.62bn (USD39.94bn) in 2014; +3.5% inlocal currency terms and -11.1% in US dollar terms. Forecast revised upwards from last quarter.


BMI Industry View
SWOT
Political
Economic
Operational Risk
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2011-2019)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Prescription Drug Market Forecast
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Norway 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2013-2019)
Macroeconomic Forecasts
Economic Analysis
Policy Response Is The Big Question
GDP By Expenditure
Table: GDP By Expenditure (Norway 2012-2019)
Industry Risk Reward Indices
Western Europe Risk/Reward Index
Norway Risk/Reward Index
Rewards
Risks
Market Overview
Industry Trends And Developments
Epidemiology
Healthcare Sector
Table: Healthcare Resources (Norway 2009-2014)
Table: Healthcare Personnel (Norway 2009-2014)
Table: Healthcare Activity (Norway 2009-2014)
Clinical Trials
Regulatory Development
Pricing Regime
Reimbursement Regime
Competitive Landscape
Table: The Top 25 Pharmaceutical Companies In Norway
Demographic Forecast
Table: Population Headline Indicators (Norway 1990-2025)
Table: Key Population Ratios (Norway 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Norway 1990-2025)
Table: Population By Age Group (Norway 1990-2025)
Table: Population By Age Group % (Norway 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report